Equities

Ainos Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AIMD:NAQ

Ainos Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.58
  • Today's Change-0.16 / -9.20%
  • Shares traded85.53k
  • 1 Year change-52.98%
  • Beta2.3914
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.

  • Revenue in USD (TTM)113.04k
  • Net income in USD-14.96m
  • Incorporated1984
  • Employees44.00
  • Location
    Ainos Inc3050 Post Oak Blvd,, Suite 510-T80HOUSTON 77056United StatesUSA
  • Phone+1 (281) 898-6586
  • Websitehttps://www.ainos.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biomx Inc0.00-37.38m9.77m52.00---------30.62-30.620.007.430.00----0.00-86.77-48.34-103.85-57.24-----------57.020.00------32.26---53.03--
LianBio - ADR0.00-87.98m9.83m163.00--0.0482-----0.8195-0.81950.001.890.00----0.00-28.62---35.22--------------0.00------43.82------
Inotiv Inc513.02m-68.63m9.98m1.95k--0.0733--0.0195-2.22-2.2215.803.960.660912.276.76263,765.60-8.84-18.23-15.66-23.6423.5826.43-13.38-27.500.2673-0.61340.75--4.5453.3636.72--21.79--
Imunon Inc0.00-14.33m10.04m25.00--2.67-----10.20-10.200.001.230.00----0.00-122.58-57.72-208.59-70.83-------7,752.42----0.00------4.58---38.98--
Calcimedica Inc0.00-23.06m10.08m14.00---------1.60-1.600.00-0.01880.00----0.00-148.18-58.12-194.91-64.99------------1.03------60.12---57.90--
KALA BIO Inc0.00-35.84m10.12m38.00---------5.94-5.940.00-1.170.00----0.00-90.62-61.19-316.35-75.37-------1,732.87---12.711.44------8.74---31.05--
Ernexa Therapeutics Inc1.00k-18.36m10.50m6.00--0.8003--10,499.80-5.32-5.320.00020.45480.0001--0.0059166.67-264.07-187.10-2,044.59-237.72100.00---1,834,000.00-3,375.91---2.730.00--755.88-50.61-105.47---19.54--
Soligenix Inc0.00-11.46m10.69m14.00--1.38-----3.66-3.660.000.77050.00----0.00-105.25-73.79-165.82-151.46--22.19---1,147.93----0.00---85.78-51.89-34.62------
Ainos Inc113.04k-14.96m11.03m44.00--0.754--97.60-4.29-4.290.03072.100.00420.123,768.002,569.09-55.34-38.46-60.63-55.2282.6235.93-13,231.35-1,122.702.67-19.920.5227---83.0212.06-7.93--10.22--
Moleculin Biotech Inc0.00-41.36m11.36m17.00---------55.88-55.880.00-13.600.00----0.00-189.07-49.52-254.72-54.93--------------------26.89---24.21--
Longeveron Inc1.44m-21.34m11.40m25.00--1.13--7.93-1.34-1.340.09090.47320.0632--6.6557,480.00-93.88-70.26-114.04-83.9274.8844.57-1,485.11-683.81----0.00--237.38-15.76-10.86--51.32--
TRON Group Inc1.01m-549.47k11.43m50.00------11.32-0.0034-0.00340.0062-0.0508------20,191.00--------60.28---110.51--0.0417-433.32----0.3272---39.70------
Sensei Biotherapeutics Inc0.00-24.14m11.47m14.00--0.4983-----19.16-19.160.0018.240.00----0.00-59.72-43.45-68.03-48.13------------0.0083------11.57--22.47--
Inhibitor Therapeutics Inc0.00-3.43m11.56m3.00--3,351.42-----0.0199-0.01990.000.000020.00----0.00-71.4917.96-72.4920.49------------0.000.00-----10.35------
OSR Holdings Inc2.52m-15.21m11.90m----0.1335--4.71-1.73-1.730.19393.460.0255-------22.03---34.38--18.35---864.91--0.2009--0.0313-------697.08------
Data as of Feb 12 2026. Currency figures normalised to Ainos Inc's reporting currency: US Dollar USD

Institutional shareholders

1.89%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 30 Sep 202558.60k0.84%
Two Sigma Investments LPas of 30 Sep 202523.01k0.33%
DRW Securities LLCas of 30 Sep 202517.77k0.26%
Vanguard Fiduciary Trust Co.as of 31 Dec 202514.95k0.21%
The Vanguard Group, Inc.as of 31 Dec 20259.28k0.13%
BlackRock Fund Advisorsas of 30 Sep 20253.07k0.04%
Tower Research Capital LLCas of 30 Sep 20251.81k0.03%
Seneschal Advisors LLCas of 30 Sep 20251.80k0.03%
Steward Partners Investment Advisory LLCas of 30 Sep 20251.21k0.02%
UBS Securities LLCas of 31 Dec 2025585.000.01%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.